For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Vyndamax and the formulated version represents a significant advancement . These novel therapies preserve the transthyretin protein, halting its destructive build-up and lessening the